ArticleApplied and environmental microbiology2013
Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates.
Article in Applied and environmental microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 95 citations in OpenAlex.
- Review
- Epidemiology ofNew microbes and new infections · 2026Article
- Genomic insights into the resistome, mobilome and functional adaptation ofMicrobial genomics · 2026Article
- From an emerging pathogen to therapeutic challenges: advances inFrontiers in microbiology · 2026Review
- Clinical and microbiologic features ofJournal of clinical microbiology · 2025Article
- Novel Insight into Dugong Mortality: First Report of SystemicAnimals : an open access journal from MDPI · 2025Article
- Development of a granular bioformulation of Achromobacter xylosoxidans AX77 16S for sustainable onion white rot management and growth enhancement.Scientific reports · 2025Article
- Highly carbapenem-resistantMicrobiology spectrum · 2025Article
- Biofilm Compositions and Bacterial Diversity on Kitchen Towels in Daily Use.Microorganisms · 2025Article
- Article
- Comprehensive analysis of microbiome biodiversity in popular date palm (Phoenix dactylifera L.) fruit varieties.Scientific reports · 2024Article
- Genomics and taxonomy of the glyphosate-degrading, copper-tolerant rhizospheric bacterium Achromobacter insolitus LCu2.Antonie van Leeuwenhoek · 2024Article
- Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains.Annals of clinical microbiology and antimicrobials · 2024Article
- Prevalence and variability of siderophore production in theMicrobiology spectrum · 2024Article
- Comparative genomics of trimethoprim-sulfamethoxazole-resistant Achromobacter xylosoxidans clinical isolates from Serbia reveals shortened variant of class 1 integron integrase gene.Folia microbiologica · 2023Article
- Effects of genetic and environmental variables on biofilm development dynamics inIranian journal of microbiology · 2023Article
- One year experience ofAccess microbiology · 2023Article
- Diverse Protein Architectures and α-ACS chemical biology · 2022Article
- An 18-Year Dataset on the Clinical Incidence and MICs to Antibiotics ofAntibiotics (Basel, Switzerland) · 2022Article
- The First Bacterial Endocarditis Due toPathogens (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Achromobacter xylosoxidans is an aerobic nonfermentative Gram-negative rod considered an important emerging pathogen among cystic fibrosis (CF) patients worldwide and among immunocompromised patients. This increased prevalence remains unexplained, and to date no environmental reservoir has been identified. The aim of this study was to identify potential reservoirs of A. xylosoxidans in hospital, domestic, and outdoor environments and to compare the isolates with clinical ones. From 2011 to 2012, 339 samples were collected in Dijon's university hospital, in healthy volunteers' homes in the Dijon area, and in the outdoor environment in Burgundy (soil, water, mud, and plants). We designed a protocol to detect A. xylosoxidans in environmental samples based on a selective medium: MCXVAA (MacConkey agar supplemented with xylose, vancomycin, aztreonam, and amphotericin B). Susceptibility testing, genotypic analysis by pulsed-field gel electrophoresis, and blaOXA-114 sequencing were performed on the isolates. A total of 50 strains of A. xylosoxidans were detected in hospital (33 isolates), domestic (9 isolates), and outdoor (8 isolates) samples, mainly in hand washing sinks, showers, and water. Most of them were resistant to ciprofloxacin (49 strains). Genotypic analysis and blaOXA-114 sequencing revealed a wide diversity among the isolates, with 35 pulsotypes and 18 variants of oxacillinases. Interestingly, 10 isolates from hospital environment were clonally related to clinical isolates previously recovered from hospitalized patients, and one domestic isolate was identical to one recovered from a CF patient. These results indicate that A. xylosoxidans is commonly distributed in various environments and therefore that CF patients or immunocompromised patients are surrounded by these reservoirs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.